New Success With Microbicides and Pre-Exposure Prophylaxis for Human Immunodeficiency Virus (HIV): Is Female-Controlled Prevention the Answer to the HIV Epidemic?

Reviews in Obstetrics and Gynecology

Khady Diouf¹  Jessica Opoku-Anane³  Nawal M Nour² 

[1] Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, MA;Department of Maternal-Fetal Medicine, Brigham and Women’s Hospital, Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA;Brigham and Women’s Hospital, Massachusetts General Hospital Integrated Residency Program, Boston, MA

关键词: HIV/AIDS;    Pre-exposure prophylaxis;    Microbicides;    Oral antiretroviral chemoprophylaxis drugs;   

DOI  :  

学科分类：医学（综合）

来源: MedReviews, LLC

【 摘 要 】

Women who cannot negotiate condom use with their partners, often due to socioeconomic factors and sexual abuse, have no means of preventing themselves from acquiring the human immunodeficiency virus (HIV). There is a need to develop HIV-preventive methods initiated and controlled by women. Microbicides and other pre-exposure prophylaxis may help fill that need. Although two decades of research on broad-spectrum microbicides have generally been disappointing, recent trials with HIV-specific agents have yielded promising initial results. A new era of clinical research involves novel biochemical prevention methods, including HIV-specific vaginal microbicides and oral antiretroviral chemoprophylaxis drugs (pre-exposure prophylaxis; PrEP) that may help provide more control for women.

【 授权许可】

Unknown